|
|
Exchange: |
N/A |
Security
Type: |
Common |
Shares
Out: |
110,820,000 |
Market
Cap: |
1.18(B) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$8.58 - $25.88 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Precision Biosciences is a clinical stage gene editing company focused on improving life by developing ex vivo allogeneic chimeric antigen receptor (CAR) T immunotherapies and in vivo therapies for genetic and infectious diseases with the application of its wholly owned proprietary ARCUS genome editing platform. Co. is simultaneously conducting a Phase 1/2a clinical trial evaluating PBCAR0191 as a potential first-in-class and a Phase 1 clinical trial evaluating PBCAR19B as, if approved, a potential CD19-targeting CAR T cell therapies in adult patients with relapsed or refractory, B-cell malignancies.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
90,000 |
189,021 |
Total Buy Value |
$0 |
$0 |
$43,200 |
$170,792 |
Total People Bought |
0 |
0 |
1 |
1 |
Total Buy Transactions |
0 |
0 |
1 |
5 |
Total Shares Sold |
2,480 |
210,683 |
365,092 |
452,513 |
Total Sell Value |
$25,523 |
$100,755 |
$167,195 |
$249,561 |
Total People Sold |
4 |
4 |
4 |
4 |
Total Sell Transactions |
5 |
9 |
12 |
17 |
End Date |
2024-02-11 |
2023-11-10 |
2023-05-12 |
2022-05-12 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Barton Shane |
VP & Corporate Controller |
|
2022-02-28 |
4 |
A |
$3.61 |
$2,747 |
D/D |
761 |
2,659 |
|
- |
|
Scimeca Dario |
General Counsel and Secretary |
|
2022-02-28 |
4 |
A |
$3.61 |
$7,397 |
D/D |
2,049 |
10,573 |
|
- |
|
Kelly John Alexander |
Chief Financial Officer |
|
2021-08-31 |
4 |
A |
$10.68 |
$10,659 |
D/D |
998 |
16,798 |
|
- |
|
Barton Shane |
VP & Corporate Controller |
|
2021-08-31 |
4 |
A |
$10.68 |
$6,451 |
D/D |
604 |
1,898 |
|
- |
|
Scimeca Dario |
General Counsel and Secretary |
|
2021-08-31 |
4 |
A |
$10.68 |
$5,853 |
D/D |
548 |
8,524 |
|
- |
|
Thomson David S. |
Chief Operating Officer |
|
2021-06-23 |
4 |
S |
$10.65 |
$319,500 |
D/D |
(30,000) |
111,513 |
|
11% |
|
Thomson David S. |
Chief Operating Officer |
|
2021-06-23 |
4 |
OE |
$1.18 |
$35,400 |
D/D |
30,000 |
141,513 |
|
- |
|
Thomson David S. |
Chief Operating Officer |
|
2021-06-21 |
4 |
S |
$10.77 |
$161,550 |
D/D |
(15,000) |
111,513 |
|
13% |
|
Thomson David S. |
Chief Operating Officer |
|
2021-06-21 |
4 |
OE |
$1.18 |
$17,700 |
D/D |
15,000 |
126,513 |
|
- |
|
Thomson David S. |
Chief Operating Officer |
|
2021-06-18 |
4 |
S |
$11.00 |
$110,000 |
D/D |
(10,000) |
111,513 |
|
8% |
|
Thomson David S. |
Chief Operating Officer |
|
2021-06-18 |
4 |
OE |
$1.18 |
$11,800 |
D/D |
10,000 |
121,513 |
|
- |
|
Thomson David S. |
Chief Operating Officer |
|
2021-06-17 |
4 |
S |
$10.44 |
$104,400 |
D/D |
(10,000) |
111,513 |
|
10% |
|
Thomson David S. |
Chief Operating Officer |
|
2021-06-17 |
4 |
OE |
$1.18 |
$11,800 |
D/D |
10,000 |
121,513 |
|
- |
|
Thomson David S. |
Chief Operating Officer |
|
2021-06-11 |
4 |
S |
$11.52 |
$345,600 |
D/D |
(30,000) |
111,513 |
|
14% |
|
Thomson David S. |
Chief Operating Officer |
|
2021-06-11 |
4 |
OE |
$1.18 |
$35,400 |
D/D |
30,000 |
141,513 |
|
- |
|
Jantz Derek |
Chief Scientific Officer |
|
2021-05-17 |
4 |
S |
$9.38 |
$187,600 |
D/D |
(20,000) |
4,032,279 |
|
-35% |
|
Jantz Derek |
Chief Scientific Officer |
|
2021-05-14 |
4 |
AS |
$9.17 |
$88,701 |
D/D |
(9,673) |
4,052,279 |
|
42% |
|
Jantz Derek |
Chief Scientific Officer |
|
2021-05-14 |
4 |
OE |
$0.04 |
$861 |
D/D |
21,514 |
4,061,952 |
|
- |
|
Jantz Derek |
Chief Scientific Officer |
|
2021-05-13 |
4 |
AS |
$9.15 |
$88,508 |
D/D |
(9,673) |
4,040,438 |
|
38% |
|
Jantz Derek |
Chief Scientific Officer |
|
2021-05-13 |
4 |
OE |
$0.04 |
$861 |
D/D |
21,514 |
4,050,111 |
|
- |
|
Kane Matthew R. |
President and CEO |
|
2021-05-13 |
4 |
AS |
$8.96 |
$86,688 |
D/D |
(9,675) |
2,013,597 |
|
38% |
|
Kane Matthew R. |
President and CEO |
|
2021-05-13 |
4 |
OE |
$0.04 |
$861 |
D/D |
21,514 |
2,023,272 |
|
- |
|
Jantz Derek |
Chief Scientific Officer |
|
2021-05-12 |
4 |
AS |
$8.72 |
$84,375 |
D/D |
(9,676) |
4,028,597 |
|
40% |
|
Jantz Derek |
Chief Scientific Officer |
|
2021-05-12 |
4 |
OE |
$0.04 |
$861 |
D/D |
21,514 |
4,038,273 |
|
- |
|
Kane Matthew R. |
President and CEO |
|
2021-05-10 |
4 |
AS |
$8.25 |
$80,405 |
D/D |
(9,746) |
2,001,758 |
|
59% |
|
179 Records found
|
|
Page 4 of 8 |
|
|